Long COVID produces fatigue that persists months after the virus has cleared. The standard explanations — tissue damage, viral persistence, psychosomatic factors — fail to explain why the fatigue correlates so poorly with initial disease severity. Patients with mild acute illness sometimes develop severe, lasting fatigue. Patients who were hospitalized sometimes recover completely.
A distinct molecular state in CD14+ monocytes — dubbed “LC-Mo” — appears specifically in long COVID patients who had mild to moderate initial disease. LC-Mo monocytes are simultaneously proinflammatory and exhausted: they produce elevated cytokines (immune activation) while showing markers of T cell exhaustion (immune suppression). The immune system is pressing the accelerator and the brake at the same time.
The LC-Mo state correlated with fatigue severity and respiratory symptoms and persisted for more than 180 days after infection. The pathways involved — JAK-STAT, interleukin-6, complement activation — are the same pathways that fight acute infection. But in long COVID, they don't turn off. The immune response that resolved the virus continues running, consuming energy, producing inflammation, and progressively exhausting the cells responsible for surveillance.
The structural insight: fatigue in long COVID is not a residual effect of the disease. It is the current cost of an immune system that never stopped fighting. The sentinel cells that should have stood down after the threat passed are still on alert, burning resources, signaling danger to tissues that are no longer in danger. The fatigue is not damage — it is expenditure. The body is tired because the immune system is working, not because something is broken. The distinction matters: damage requires repair, but inappropriate activation requires only a signal to stop.